(Q34322230)

English

Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010. (English)

1 reference

Europe PubMed Central

1 August 2017

author name string

Lewis Couchman

1

1 reference

Europe PubMed Central

1 August 2017

Sally V J Bowskill

2

1 reference

Europe PubMed Central

1 August 2017

Simon Handley

3

1 reference

Europe PubMed Central

1 August 2017

Maxine X Patel

4

1 reference

Europe PubMed Central

1 August 2017

Robert J Flanagan

5

1 reference

Europe PubMed Central

1 August 2017

publication date

3 July 2012

1 reference

Europe PubMed Central

1 August 2017

Early Intervention in Psychiatry: the development, onset and treatment of emerging mental disorders

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

122-130

1 reference

Europe PubMed Central

1 August 2017

2

1 reference

Europe PubMed Central

1 August 2017

Teenage psychoses--epidemiology, classification and reduced optimality in the pre-, peri- and neonatal periods.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Management of schizophrenia in children and adolescents: focus on pharmacotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Increased developmental deviance and premorbid dysfunction in early onset schizophrenia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Treatment of early-onset schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Decision making about children with psychotic symptoms: using the best evidence in choosing a treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

New advances in pharmacotherapy for early psychosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

EEG changes with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Haematological toxicity of clozapine and some other drugs used in psychiatry.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Therapeutic monitoring of new antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Clozapine-induced seizures: recognition and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Dried blood spots, pharmacokinetic studies and better medicines for children.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Principles of therapeutic drug monitoring.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Clozapine use in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2012.00374.X

21 January 2018

Identifiers

10.1111/J.1751-7893.2012.00374.X

1 reference

Europe PubMed Central

1 August 2017

release_ucnfgbvdqza35ilvqjo22ceauy

1 reference

https://api.fatcat.wiki/v0/release/ucnfgbvdqza35ilvqjo22ceauy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34322230&oldid=1844817373"